TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20538208

Group type: EXPERIMENTAL
Intervention: Wound infiltration of ropivacaine
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no wound infiltration)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both groups (ropivacaine and control)
Number of subjects: 102
Study: 18772244

Group type: EXPERIMENTAL
Intervention: Testosterone supplements
Number of subjects: 1276

Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 1276

Group type: COMPARATOR
Intervention: PCOS, acne, hirsutism
Number of subjects: 1276
Study: 16438129

Group type: EXPERIMENTAL
Intervention: Artekin (dihydroartemisinin 40 mg and piperaquine 320 mg) given once a day for 3 days (Group B)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Artesunate 4 mg/kg/day and mefloquine 8 mg/kg/day orally once a day for 3 days (Group A)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Artekin (dihydroartemisinin 40 mg and piperaquine 320 mg)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Artesunate 4 mg/kg/day and mefloquine 8 mg/kg/day
Number of subjects: 180
Study: 12903625

Group type: EXPERIMENTAL
Intervention: Pentaglobin (infused intravenously at 12 mL/h for 3 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Previous treatment period without Pentaglobin
Number of subjects: 11
Study: 10573505

Group type: EXPERIMENTAL
Intervention: Active condition (physical activity)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Rest condition (no physical activity)
Number of subjects: 10
Study: 7564347

Group type: EXPERIMENTAL
Intervention: UP 269-6 (180 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: UP 269-6 (>= 40 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Enalapril 20 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: UP 269-6
Number of subjects: 16
Study: 1939923

Group type: EXPERIMENTAL
Intervention: Exposure treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 339250

Group type: EXPERIMENTAL
Intervention: Transverse carpal ligament release alone
Number of subjects: 22

Group type: COMPARATOR
Intervention: Transverse carpal ligament release, external neurolysis of the median nerve, flexor synovectomy, and intraoperative corticosteroid instillation
Number of subjects: 22
Study: 31770456

Group type: EXPERIMENTAL
Intervention: Itraconazole (P-glycoprotein inhibitor)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rifampicin (P-glycoprotein inducer)
Number of subjects: 36
Study: 30908592

Group type: EXPERIMENTAL
Intervention: Restrictive oxygen therapy (no supplemental oxygen if SpO2 ≥ 94%, n=21)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Liberal oxygen therapy (intubated patients: FiO2 1.0 in trauma bay, 0.8-1.0 elsewhere; spontaneously breathing patients: 15 L/min via non-rebreather mask, n=20)
Number of subjects: 41
Study: 28394418

Group type: EXPERIMENTAL
Intervention: Peginterferon beta‐1a
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Every‐2‐week dosing regimen of Peginterferon beta‐1a
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26081864

Group type: EXPERIMENTAL
Intervention: Rehab-let (touchscreen tablet self-training protocol)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional self-training program using therapeutic aids (balls, blocks, pegs)
Number of subjects: 40
Study: 23569345

Group type: EXPERIMENTAL
Intervention: 2 mg/kg IL‐1Ra via ear vein 18 h, 2 d and 4 d after D‐gal induction (Group B)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 2 mg/kg IL‐1Ra via ear vein 18 h after D‐gal induction, MSCs transplantation at 24 h after D‐gal induction, and 2 mg/kg IL‐1Ra via ear vein 1 d and 3 d after surgery (Group D)
Number of subjects: 28

Group type: COMPARATOR
Intervention: 40 mL saline via portal vein 24 h after D‐gal induction (Group A)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Approximately 1 × 10(8) GFP‐MSCs suspended in 40 mL normal saline via portal vein 24 h after D‐gal induction (Group C)
Number of subjects: 28
Study: 22143217

Group type: EXPERIMENTAL
Intervention: Oral care education for caregivers (6 weeks duration)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual oral care from control group caregivers
Number of subjects: 54
Study: 19153867

Group type: EXPERIMENTAL
Intervention: Individualized-vibration group
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Fixed-vibration group
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 17892982

Group type: EXPERIMENTAL
Intervention: Atenolol therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Losartan therapy
Number of subjects: 0
Study: 15177489

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 252

Group type: COMPARATOR
Intervention: Itraconazole
Number of subjects: 252
Study: 11474773

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 20 mg sodium rabeprazole
Number of subjects: 18
Study: 9604880

Group type: EXPERIMENTAL
Intervention: Nicotinamide (slow release, 1.2 g x m(‐2) x day(‐1))
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 7924780

Group type: EXPERIMENTAL
Intervention: Impaired awareness of hypoglycemia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal awareness of hypoglycemia
Number of subjects: 60
Study: 3260759

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 70

Group type: COMPARATOR
Intervention: Pentamidine
Number of subjects: 70
Study: 31736283

Group type: EXPERIMENTAL
Intervention: Healthy Conversation Skills (HCS) intervention
Number of subjects: 0
Study: 29880010

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28398946

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Short-Duration HIIT
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Exercise intervention (all groups combined)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: All groups (HIIT, MICT, Short-Duration HIIT)
Number of subjects: 46
Study: 26817206

Group type: EXPERIMENTAL
Intervention: Oral vitamin D supplement (2,000 IUs/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 23284036

Group type: EXPERIMENTAL
Intervention: Protocolized patient‐tailored treatment (PPT) of symptoms
Number of subjects: 152
Study: 21640089

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Baseline median values of biomarkers
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison between mild and moderate GP subgroups
Number of subjects: 40
Study: 19084937

Group type: EXPERIMENTAL
Intervention: 4-week pegylated interferon alpha-2a (peg-IFN-alpha 2a) monotherapy, 180 microg or 90 microg once weekly
Number of subjects: 33

Group type: COMPARATOR
Intervention: 12-week pegylated interferon alpha-2a (peg-IFN-alpha 2a) monotherapy, 180 microg or 90 microg once weekly
Number of subjects: 33
Study: 18039239

Group type: EXPERIMENTAL
Intervention: Intensive group physical therapy (PT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 96
Study: 14979498

Group type: EXPERIMENTAL
Intervention: Tiotropium (18 microg once daily)
Number of subjects: 519

Group type: COMPARATOR
Intervention: Ipratropium (2 puffs of 20 microg administered four times daily)
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 519

Group type: COMPARATOR
Intervention: Ipratropium
Number of subjects: 519
Study: 11568834

Group type: EXPERIMENTAL
Intervention: Postoperative compression
Number of subjects: 130
Study: 9652994

Group type: EXPERIMENTAL
Intervention: MFP plus calcium (20 mg of equivalent fluoride + 1000 mg calcium)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Calcium only
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: MFP plus calcium
Number of subjects: 200
Study: 10150434

Group type: EXPERIMENTAL
Intervention: Electrosurgical loop conization
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CO2 laser conization
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cold knife conization
Number of subjects: 30

Group type: COMPARATOR
Intervention: All methods (cold knife, laser, electrosurgical loop)
Number of subjects: 30
Study: 3135831

Group type: EXPERIMENTAL
Intervention: 17 alpha-hydroxyprogesterone caproate
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 31857217

Group type: EXPERIMENTAL
Intervention: Lurasidone (20-80 mg/day)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study: 30599772

Group type: EXPERIMENTAL
Intervention: Interactive computer play training (4 times per week, 20 minutes per session for 6 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (usual physiotherapy programme)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Interactive computer play training
Number of subjects: 18
Study: 28402092

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided epidural placement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sham (non-ultrasound) epidural placement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no epidural)
Number of subjects: 0
Study: 25572878

Group type: EXPERIMENTAL
Intervention: Charité Cesarean Birth (CCB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classical cesarean section (Control)
Number of subjects: 0
Study: 24928083

Group type: EXPERIMENTAL
Intervention: FOLFOX4 plus cetuximab
Number of subjects: 2559

Group type: COMPARATOR
Intervention: FOLFOX4 alone
Number of subjects: 2559
Study: 22980891

Group type: EXPERIMENTAL
Intervention: L‐FVOO (250 mg total phenols/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: M‐FVOO (500 mg total phenols/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: H‐FVOO (750 mg total phenols/kg)
Number of subjects: 12
Study: 19939281

Group type: EXPERIMENTAL
Intervention: Laterally wedged insoles (5 degrees)
Number of subjects: 20
Study: 17244785

Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg daily (PIO)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 31
Study: 16286549

Group type: EXPERIMENTAL
Intervention: Mild Cognitive Impairment (MCI) diagnosis based on comprehensive neuropsychological, functional, and neurologic assessments.
Number of subjects: 1315

Group type: EXPERIMENTAL
Intervention: Age and education as factors in MCI diagnosis.
Number of subjects: 1315

Group type: EXPERIMENTAL
Intervention: APOE E4 allele association with MCI.
Number of subjects: 1315
Study: 11965508

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (60 mg RE to mothers and 7.5 mg RE to infants with each OPV dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (given to mothers and infants at each OPV contact)
Number of subjects: 0
Study: 9825815

Group type: EXPERIMENTAL
Intervention: Increased doses of tacrolimus (median increase of 1.89-fold, range: 1.2-5 mg)
Number of subjects: 10
Study: 8008540

Group type: EXPERIMENTAL
Intervention: Goat's milk
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cow's milk
Number of subjects: 30
Study: 2466045

Group type: EXPERIMENTAL
Intervention: Octreotide (50 micrograms, sc)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Octreotide (50 micrograms, twice daily, sc)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Octreotide (50 micrograms, sc) given 45 min before flush stimulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo administered in the same way
Number of subjects: 20
Study: 30810750

Group type: EXPERIMENTAL
Intervention: Motor-based problem solving intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Optimal movement patterns intervention
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 20
Study: 27936452

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0
Study: 25995333

Group type: EXPERIMENTAL
Intervention: Vagitocin 400 IU
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Vagitocin 100 IU
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 24196330

Group type: EXPERIMENTAL
Intervention: Nd:YAG 1440 nm laser treatment
Number of subjects: 15
Study: 20971520

Group type: EXPERIMENTAL
Intervention: AF+C
Number of subjects: 189

Group type: COMPARATOR
Intervention: CF
Number of subjects: 189
Study: 18203019

Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m2 once weekly for 4 weeks
Number of subjects: 123

Group type: COMPARATOR
Intervention: Rituximab alone (n = 36)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Rituximab in combination with interferon alpha-2a (IFN) (n = 33)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Minimal residual disease (MRD) evaluation in patients who achieved CR
Number of subjects: 123
Study: 16402269

Group type: EXPERIMENTAL
Intervention: Bendamustine and prednisone (BP)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Melphalan and prednisone (MP)
Number of subjects: 131
Study: 14609612

Group type: EXPERIMENTAL
Intervention: Amiodarone with percutaneous balloon mitral commissurotomy
Number of subjects: 38

Group type: COMPARATOR
Intervention: No amiodarone
Number of subjects: 38
Study: 10910828

Group type: EXPERIMENTAL
Intervention: Full-dose aprotinin regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Half-dose aprotinin regimen
Number of subjects: 0
Study: 8760643

Group type: EXPERIMENTAL
Intervention: 2.5 mg of lorazepam, orally, one hour before induction of anaesthesia
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo, orally, one hour before induction of anaesthesia
Number of subjects: 26
Study: 1425205

Group type: EXPERIMENTAL
Intervention: Seaprose (60 mg/8 h) plus erythromycin (500 mg/8 h)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Erythromycin (500 mg/8 h) plus placebo
Number of subjects: 40
Study: 3967167

Group type: EXPERIMENTAL
Intervention: Intravenous dacarbazine plus intradermal injection of the methanol‐extracted residue of bacillus Calmette‐Guerin (BCG)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Intravenous dacarbazine alone
Number of subjects: 70
Study: 29276857

Group type: EXPERIMENTAL
Intervention: Stroop Color and Word test to induce mental fatigue
Number of subjects: 16

Group type: COMPARATOR
Intervention: Watching an emotionally neutral video
Number of subjects: 16
Study: 27251474

Group type: EXPERIMENTAL
Intervention: Three additional imbricating figure‐of‐X sutures (Arm 2)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Single‐layer continuous closure (Arm 1)
Number of subjects: 263
Study: 24662230

Group type: EXPERIMENTAL
Intervention: Additional repeated sprint training (RS)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normal training
Number of subjects: 13
Study: 20977661

Group type: EXPERIMENTAL
Intervention: Household salt iodine content
Number of subjects: 2488

Group type: EXPERIMENTAL
Intervention: Direct iodine supplementation during pregnancy
Number of subjects: 2488
Study: 21190639

Group type: EXPERIMENTAL
Intervention: Medication switches
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Discontinuations
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Other access problems
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Multiple access problems
Number of subjects: 908

Group type: COMPARATOR
Intervention: No access problems
Number of subjects: 908
Study: 19007605

Group type: EXPERIMENTAL
Intervention: Hormonal contraception
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emergency contraception
Number of subjects: 0
Study: 15673878

Group type: EXPERIMENTAL
Intervention: Small-dose IV ketamine (0.5 mg/kg bolus followed by 3 mcg/kg/min during surgery and 1.5 mcg/kg/min for 48 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small-dose IV ketamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 14600187

Group type: EXPERIMENTAL
Intervention: Fenoldopam mesylate (0.05 microg/kg/min titrated to 0.10 microg/kg/min)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Fenoldopam mesylate
Number of subjects: 315
Study: 10992661

Group type: EXPERIMENTAL
Intervention: Framing the health plan decision using a risk message
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard framing of health plan choice
Number of subjects: 0
Study: 8866316

Group type: EXPERIMENTAL
Intervention: Demineralized freeze‐dried bone allograft reconstituted with 50 mg/ml tetracycline (DFDBA + TCN)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Demineralized freeze‐dried bone allograft alone (DFDBA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Debridement only (D)
Number of subjects: 15
Study: 1333782

Group type: EXPERIMENTAL
Intervention: Single, high dose of aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low chloride cough challenge
Number of subjects: 0
Study: 6474351

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg and dipyridamole 75 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 30351167

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 0
Study: 30063860

Group type: EXPERIMENTAL
Intervention: Ta-1 plus ETV
Number of subjects: 690

Group type: COMPARATOR
Intervention: ETV monotherapy
Number of subjects: 690
Study: 26850868

Group type: EXPERIMENTAL
Intervention: Sialendoscopy
Number of subjects: 20
Study: 24587006

Group type: EXPERIMENTAL
Intervention: Subcutaneous palonosetron
Number of subjects: 25

Group type: COMPARATOR
Intervention: Intravenous palonosetron
Number of subjects: 25
Study: 21769988

Group type: EXPERIMENTAL
Intervention: Information about the association between cognitive problems and chemotherapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: No information about the association between cognitive problems and chemotherapy
Number of subjects: 150
Study: 19540633

Group type: EXPERIMENTAL
Intervention: Nursing student mentoring programs
Number of subjects: 0
Study: 18093331

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy (8 weekly lessons, support by e-mail)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Internet-based problem-solving therapy (5 weekly lessons, support by e-mail)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group (receives intervention 3 months later)
Number of subjects: 0
Study: 16357163

Group type: EXPERIMENTAL
Intervention: GDNF treatment in pancreatic cancer cells with G691S RET polymorphism
Number of subjects: 0

Group type: COMPARATOR
Intervention: GDNF treatment in pancreatic cancer cells without specific mention of RET polymorphism
Number of subjects: 0
Study: 11984746

Group type: EXPERIMENTAL
Intervention: PD 123319 (8 microg/minute)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 10919583

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1.5 g twice daily
Number of subjects: 150

Group type: COMPARATOR
Intervention: Azathioprine (AZA) 1-3 mg/kg daily
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 150
Study: 9044338

Group type: EXPERIMENTAL
Intervention: Fixed dialysate sodium (140 meq/dl) and fixed ultrafiltration rate (Protocol A)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Variable sodium dialysate (160-140 meq/dl) and variable ultrafiltration (Protocol B)
Number of subjects: 10
Study: 1526096

Group type: EXPERIMENTAL
Intervention: i.m. immunoglobulins and oral polyvalent bacterial vaccine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: vaccine only
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no prophylactic treatment)
Number of subjects: 90
Study: 2862594

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, 5-fluorouracil)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: CMF + T (cyclophosphamide, methotrexate, 5-fluorouracil, tamoxifen)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: CMF + T
Number of subjects: 153
Study: 31295708

Group type: EXPERIMENTAL
Intervention: Online multi-component positive psychology intervention over 8 weeks
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 128
Study: 29154271

Group type: EXPERIMENTAL
Intervention: Subcutaneous adipose tissue biopsies from AD patients
Number of subjects: 80

Group type: COMPARATOR
Intervention: Subcutaneous adipose tissue biopsies from cognitively healthy proxies
Number of subjects: 80
Study: 26328542

Group type: EXPERIMENTAL
Intervention: Water-based core stability exercises
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Land-based core stability exercises
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 31
Study: 24041789

Group type: EXPERIMENTAL
Intervention: 7.5‐µg dose of A/Vietnam vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Booster immunization with A/Indonesia(H5N1) vaccine
Number of subjects: 0
Study: 22435937

Group type: EXPERIMENTAL
Intervention: Non-high-density lipoprotein cholesterol
Number of subjects: 1173
Study: 20085866

Group type: EXPERIMENTAL
Intervention: Plasma nucleosome levels before therapy cycles 2 and 3
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Plasma nucleosome levels before the second cycle
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Plasma nucleosome levels before cycle 2
Number of subjects: 134
Study: 17658394

Group type: EXPERIMENTAL
Intervention: Fludarabine plus cyclophosphamide
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Fludarabine
Number of subjects: 777

Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 777
Study: 16259492

Group type: EXPERIMENTAL
Intervention: Problem-based empowerment patient education program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monthly support group or monthly phone call from a nurse (follow-up conditions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 0
Study: 12106618

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (88 microg, twice daily for 6 weeks)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Zafirlukast (20 mg, twice daily for 6 weeks)
Number of subjects: 440